Farxiga
Pricing Report NDC 0003-1427-11

View Wholesale Price per Unit, Acquisition Costs, and Historic Pricing Trends

Current Package Pricing Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

The latest wholesale acquisition cost for Farxiga (NDC 0003-1427-11) is $13.78769 per EA. This benchmark price is based on the National Average Drug Acquisition Cost (NADAC) and has been effective since Mar 22, 2017.

As a provided by E.r. Squibb & Sons, L.l.c., this medication is distributed in a 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC configuration. The pricing data is derived from C/I - Chain or Independent Pharmacy surveys, reflecting the actual invoice prices paid by community pharmacies to drug wholesalers.

NADAC Pricing Summary

NADAC pricing snapshot for this package NDC

Acquisition Cost
$13.78769
Per EA

Effective Date
Mar 22, 2017
Billable Units
30 EA
Estimated Package Price
$413.63
Data Status
As of Apr 26, 2017
C/I - Chain or Independent Pharmacy
Package NDC
Description
30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC
Pricing Methodology Explanation
The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file.

Historical Pricing Trends & Acquisition Cost Benchmarks

Since Apr 2014, the NADAC wholesale price for (NDC ) has moved within a range of $9.28674 to $13.78769 per EA. Over this 2 years and 10 months period, the pricing trend reflects the shifting acquisition costs reported by retail and chain pharmacies to the Centers for Medicare and Medicaid Services (CMS). The following interactive chart and historical table detail every recorded price adjustment based on these federal surveys.

Price Range
$9.2867 - $13.7877
Market Volatility
48.47% Variance
Latest Trend
0.05%
Date Unit Price Unit Source Method Rate
Mar 22, 2017 $13.78769 EAC/I - Chain or Independent PharmacyCode 1B - Brand
Mar 22, 2017 $13.78769 EAC/I - Chain or Independent PharmacyCode 2B - Brand
Feb 22, 2017 $13.78069 EAC/I - Chain or Independent PharmacyCode 3B - Brand
Jan 18, 2017 $13.78677 EAC/I - Chain or Independent PharmacyCode 3B - Brand
Apr 11, 2016 $12.60567 EAC/I - Chain or Independent PharmacyCode 2B - Brand
Apr 11, 2016 $12.60567 EAC/I - Chain or Independent PharmacyCode 3B - Brand
Dec 23, 2015 $11.68306 EAC/I - Chain or Independent PharmacyCode 1B - Brand
Dec 23, 2015 $11.68306 EAC/I - Chain or Independent PharmacyCode 2B - Brand
Nov 18, 2015 $11.72436 EAC/I - Chain or Independent PharmacyCode 3B - Brand
Feb 16, 2015 $11.09067 EAC/I - Chain or Independent PharmacyCode 2B - Brand
Feb 16, 2015 $11.09067 EAC/I - Chain or Independent PharmacyCode 3B - Brand
Feb 16, 2015 $11.09067 EAC/I - Chain or Independent PharmacyCode 4B - Brand
Oct 22, 2014 $10.09169 EAC/I - Chain or Independent PharmacyCode 1B - Brand
Oct 22, 2014 $10.09169 EAC/I - Chain or Independent PharmacyCode 2B - Brand
Aug 15, 2014 $10.05189 EAC/I - Chain or Independent PharmacyCode 2B - Brand
Aug 15, 2014 $10.05189 EAC/I - Chain or Independent PharmacyCode 3B - Brand
May 21, 2014 $9.31585 EAC/I - Chain or Independent PharmacyCode 1B - Brand
May 21, 2014 $9.31585 EAC/I - Chain or Independent PharmacyCode 2B - Brand
Apr 23, 2014 $9.28674 EAC/I - Chain or Independent PharmacyCode 1, 6B - Brand

Pricing Methodology Legend

  • Code 1: The NADAC was calculated using information from the most recently completed pharmacy survey.
  • Code 2: The average acquisition cost of the most recent survey was within ± 2% of the current NADAC; therefore, the NADAC was carried forward from the previous file.
  • Code 3: The NADAC based on survey data has been adjusted to reflect changes in published pricing, or as a result of an inquiry to the help desk.
  • Code 4: The NADAC was carried forward from the previous file.
  • Code 6: The CMS Covered Outpatient File drug category type of S/I/N (Single Source/Innovator/Non-Innovator) has not been applied. Most S/I drugs with the same strength, dosage form and route of administration were grouped together for the purpose of the NADAC calculation and N drugs were also grouped together. In some cases, however, in calculating a NADAC, the CMS S/I/N designation was not applied when the state Medicaid brand or generic payment practices for these drugs generally differed from the CMS Covered Outpatient File designation.

Understanding NADAC Pricing Data

The National Average Drug Acquisition Cost (NADAC) is compiled by the Centers for Medicare and Medicaid Services (CMS). This data is derived from random monthly surveys of more than 60,000 pharmacies across all 50 states.


Important Price Distinction:

The prices listed on this page represent the wholesale invoice price paid by pharmacies to acquire the drug. This is NOT the retail price paid by consumers at the pharmacy counter. Final patient costs typically include pharmacy markups, professional dispensing fees, and insurance adjustments.

NADAC Pricing Data Last Updated on: July 08, 2026